Equities

Fusion Antibodies PLC

FAB:LSE

Fusion Antibodies PLC

Actions
Health CareHealth Care Providers
  • Price (GBX)4.05
  • Today's Change-0.10 / -2.41%
  • Shares traded347.21k
  • 1 Year change+12.50%
  • Beta0.3976
Data delayed at least 20 minutes, as of Nov 12 2024 16:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

  • Revenue in GBP (TTM)1.14m
  • Net income in GBP-2.23m
  • Incorporated2000
  • Employees31.00
  • Location
    Fusion Antibodies PLCSpringbank Industrial Estate1 Springbank RoadBELFAST BT17 0QLUnited KingdomGBR
  • Phone+44 289 043 2800
  • Fax+44 289 002 0446
  • Websitehttps://fusionantibodies.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ovoca Bio PLC0.00-3.29m1.59m5.00--0.8573-----0.0388-0.03470.000.0210.00----0.00-88.55-25.19-100.85-27.65------------0.00------9.05------
ValiRx Plc9.60k-1.97m2.02m8.00--0.5245--210.24-0.0172-0.01720.000080.02910.0025--0.0639---53.19-50.57-51.14-54.7785.00---21,512.29-103,908.506.27--0.0048------13.89---1.13--
TheraCryf PLC396.00k-3.14m2.56m9.00--0.7045--6.47-0.0114-0.01140.00140.00850.0858--0.976644,000.00-67.93-42.50-81.69-46.66-----792.17-1,482.46----0.00---10.41--22.41------
N4 Pharma PLC5.86k-1.12m2.57m5.00--2.05--437.90-0.0042-0.00420.000020.00320.0041--0.04211,172.00-79.19-57.05-83.28-61.13-----19,152.56-309,312.80---3,023.170.00-----51.52-24.05------
Fusion Antibodies PLC1.14m-2.23m3.98m31.00--2.21--3.51-0.0426-0.04260.02050.01880.50692.362.0236,645.16-99.33-41.50-147.47-52.23-3.9640.19-195.95-56.923.09-1,144.000.0234---60.84-12.2414.25---72.95--
Genflow Biosciences PLC0.00-1.53m6.29m5.00--7.33-----0.0051-0.00510.000.00250.00----0.00-93.85---118.87--------------0.00-------21.97------
ImmuPharma PLC-69.96k-2.46m6.88m5.00--2.56-----0.0065-0.0065-0.00020.0065-0.019-----13,992.00-66.99-86.13-111.20-106.39-------8,634.98---7.270.00------23.26------
LungLife AI Inc22.53k-3.47m7.23m15.00--0.3528--321.01-0.1304-0.13040.00080.24190.0027--2.901,502.32-42.18---47.78--100.00---15,403.45------0.0259--91.67--28.83------
Cizzle Biotechnology Holdings PLC0.00-2.70m7.53m67.00--9.49-----0.0073-0.00730.000.0020.00-------146.70-144.15-157.81-167.75-----------0.450.00-------88.27------
IXICO PLC6.00m-1.87m8.11m89.00--0.4215--1.35-0.0386-0.03860.12410.20760.4725--3.5467,415.73-14.694.35-16.585.3346.9062.09-31.106.61----0.03120.00-22.894.32-214.15--92.12--
Synairgen plc0.00-6.92m9.28m36.00--0.9645-----0.0344-0.03440.000.04750.00----0.00-47.18-54.01-54.24-60.02------------0.00------52.35---26.64--
OptiBiotix Health PLC569.00k-2.98m12.24m5.00--1.66--21.52-0.0317-0.03170.00610.07520.06341.351.07113,800.00-33.2516.82-34.8517.5247.9853.03-524.43183.495.36-2.030.00100.1440.924.60-178.82------
Hemogenyx Pharmaceuticals PLC0.00-5.18m15.57m17.00--5.08-----0.0042-0.00420.000.00230.00----0.00-77.79-82.19-85.95-95.97-----------19.940.4794-------68.14--36.68--
Data as of Nov 12 2024. Currency figures normalised to Fusion Antibodies PLC's reporting currency: UK Pound GBX

Institutional shareholders

13.67%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 07 Mar 20246.40m6.71%
Rathbones Investment Management Ltd.as of 07 Mar 20244.51m4.73%
Octopus Investments Ltd.as of 12 Jun 20231.48m1.56%
Canaccord Genuity Wealth Ltd.as of 31 Mar 2024640.03k0.67%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.